Alprazolam

Xanax immediate-release treats acute generalized anxiety disorder and panic disorder with or without agoraphobia in adults. Xanax XR treats adult panic disorder with or without agoraphobia; its label does not include GAD.

Pediatric safety/effectiveness is not established. IR evidence is primarily short-term; XR longer-term efficacy has not been systematically evaluated and use beyond 8 weeks requires reassessment. This profile excludes ODT, oral concentrate and off-label pediatric/insomnia regimens; verify other products separately.

IR geriatric/hepatic starting dose: 0.25 mg two or three times daily, increasing only if needed/tolerated; reduce further if adverse effects. XR geriatric/hepatic starting dose: 0.5 mg once daily, cautiously titrated. No numeric renal adjustment is provided in these selected labels. Swallow XR whole without dividing/crushing/chewing. Patients on divided IR may switch under supervision to the same total daily dose as once-daily XR, followed by clinical reassessment.

Labels recommend reduction by no more than 0.5 mg every 3 days; this is a ceiling on reduction speed, not a mandatory schedule. Many patients need a slower individualized taper, pauses or return to the prior tapered dose if withdrawal emerges. For ritonavir initiated with alprazolam or added to stable treatment, halve alprazolam’s recommended dose; titrate back toward the target after 10–14 days of coadministration. No reduction is required by this label when ritonavir has already been taken >10–14 days. This time-dependent exception requires prescriber supervision; never extrapolate it to other strong CYP3A inhibitors.

Known alprazolam or other benzodiazepine hypersensitivity; concurrent strong CYP3A inhibitors, such as ketoconazole/itraconazole/clarithromycin, except the separately managed ritonavir exception. The selected current labels do not list acute narrow-angle glaucoma as a formal contraindication; do not import obsolete product wording.

Both selected labels have a boxed warning for concomitant opioid risks; abuse, misuse and addiction; and dependence/withdrawal reactions. Potential outcomes include profound sedation, respiratory depression, coma, overdose/death and life-threatening withdrawal seizures.

Reported reactions include drowsiness, impaired coordination, light-headedness, hypotension, dysarthria, memory/cognitive effects and libido changes. Serious reports include angioedema, paradoxical agitation, seizures and respiratory depression. Overdose needs emergency airway/supportive monitoring, particularly with opioids/alcohol. Flumazenil can precipitate withdrawal/seizures, especially with dependence or mixed ingestion; its use is a specialist decision and does not replace supportive care.

Observational benzodiazepine data do not show a clear major-birth-defect association, but this does not establish absence of risk. Late pregnancy can cause neonatal respiratory depression, hypotonia or withdrawal; monitor/manage exposed newborns and discuss the pregnancy registry. Alprazolam enters human milk; infant sedation/poor feeding/poor weight gain are reported with benzodiazepines. Both selected labels advise against breastfeeding during treatment.

Pediatric safety/effectiveness is not established. Older patients have reduced clearance/higher concentrations and greater sensitivity; selected starting doses are IR 0.25 mg two/three times daily or XR 0.5 mg once daily, adjusted to response/tolerance.

Hepatic disease reduces clearance; alcoholic liver disease studies showed mean half-life ~19.7 hours versus ~11.4 in controls. Follow lower product-specific hepatic starts. Selected labels do not supply a renal dose formula; review kidney disease, respiratory status, sedation and concomitant medicines individually.

Binds the benzodiazepine site of GABAA receptors and enhances GABA-mediated synaptic inhibition. This contributes to anxiolytic/panic benefit and CNS depression.

Absorption

IR peak ~1–2 hours; morning XR peak ~10 hours. XR absolute bioavailability ~90%, with ~100% relative bioavailability to IR.

Distribution / metabolism

~80% protein-bound; primarily CYP3A4 metabolism. Major hydroxyl metabolites have low concentrations/potency.

Elimination

Primarily urinary parent/metabolites. Mean IR half-life ~11.2 hours (range ~6.3–26.9); XR studies ~10.7–15.8 hours.

Exposure variation

Older age, liver disease and metabolic interactions can prolong/increase exposure.

• Follow anxiety/panic benefit, sedation, coordination, falls, cognition and respiratory function.
• Assess depression/suicidality, misuse/addiction and physical dependence; review prescription quantity and storage.
• Reconcile opioids, alcohol, other sedatives and CYP3A medicines; monitor digoxin when relevant.
• During taper, distinguish recurrence/rebound from withdrawal and slow or pause the plan when needed.

• Take only the prescribed dose; never share and keep securely away from children/others.
• Do not stop abruptly or rapidly reduce; contact the prescriber before running out.
• Avoid alcohol and unsupervised sedative/opioid combinations; emergency help is needed for shallow breathing or extreme sleepiness.
• Do not divide/crush/chew XR. Discuss pregnancy/breastfeeding and follow approved disposal directions for unused controlled medicine.

Dosage form / strength

Immediate-release scored tablet · 0.25 mg

Distributor

Viatris Specialty LLC

Appearance / imprint

White, oval · XANAX 0.25

Example NDC

58151-452-01 · 100 tablets

Selected Xanax IR tablets: 0.25, 0.5, 1 and 2 mg. Xanax XR tablets: 0.5, 1, 2 and 3 mg; XR 0.5 mg is white/pentagonal, marked X / 0.5. Oral concentrates/ODT are outside this profile and require their own measuring/administration directions.

Store selected IR at 20–25°C, protected from light, in tight/light-resistant child-resistant containers. XR: 20–25°C with excursions 15–30°C in tight child-resistant containers. Store securely, never share and follow take-back/disposal guidance; keep out of children’s reach.